TIDMFDBK

Feedback PLC

06 October 2015

Feedback plc

("Feedback" or the "Company")

NHS England "Alert" published on the potential application of TexRAD for assessing patients with lung cancer

Feedback plc (AIM: FDBK), the medical imaging software company is pleased to announce that the research arm of NHS England has published an "Alert" on the potential application of Feedback's TexRAD CT texture analysis software for assessing patients with lung cancer. The National Institute for Health Research through its Horizon Scanning Research and Intelligence Centre (NIHR HSRIC) based at the University of Birmingham, England has also posted the Alert on its publicly accessible website. (www.hsric.nihr.ac.uk)

NIHR HSRIC is an academic unit which independently investigates and provides advanced notice of new and emerging medical devices and diagnostics that have the potential to positively impact upon the NHS within the next two years. Before writing the Alert, NIHR HSRIC looked at TexRAD CT texture analysis technology and its potential use for assessing patients with different cancers but particularly for those with lung cancer. The Alert will be distributed within the NHS and to national healthcare organisations and policy makers such as the National Institute for Health and Care Excellence (NICE) and the UK National Screening Committee.

Dr. Balaji Ganeshan, Chief Scientist & New Business Officer of the Company's subsidiaries TexRAD Ltd & Cambridge Computed Imaging Ltd commented:

"The Alert from the NHS's research arm is a significant step towards potentially obtaining NICE approval for TexRAD to be used as a clinical tool for assessing patients with lung cancer. This adds to the recently announced clinical adoption study focused on lung cancer being undertaken by Professor Ken Miles at the Princess Alexandra Hospital, Brisbane, Australia. "

For further information contact:

 
 Feedback plc                         Tel: 01954 
                                          718072 
 Simon Barrell / Trevor Brown 
  / Tom Charlton 
 
 Sanlam Securities UK (Nominated   Tel: 020 7628 
  Adviser and Joint Broker)                 2200 
 Simon Clements / Virginia Bull 
 
 Peterhouse Corporate Finance      Tel: 020 7469 
  Ltd (Joint Broker)                        0936 
 Lucy Williams / Duncan Vasey

Notes to editors:

TexRAD is a novel sophisticated imaging risk stratification research tool that analyses the textures in existing radiological scans. This research software application analyses textures, detecting and measuring tumour heterogeneity (complexity) from these images, revealing more information from medical images than is readily visible to the naked eye. Research to date has shown that TexRAD could potentially assist the clinician (as an 'Imaging-Biomarker') in confident decision-making: it has the potential to assess the prognosis, disease-severity (e.g. risk of metastases) and response evaluation of patients with cancer. Currently TexRAD research has shown great potential in many different oncological sites, including, colorectal, breast, lung, prostate, oesophageal, head & neck, lymphoma, liver and renal cancers and could potentially be employed as a heterogeneity assessing tool in the era of 'Precision and Personalized Medicine'. TexRAD is manufactured under licence by company Cambridge Computed Imaging Ltd, a subsidiary of Feedback plc. More information is available on www.fbk.com and www.texrad.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAPKADNFBDKFKK

(END) Dow Jones Newswires

October 06, 2015 04:45 ET (08:45 GMT)

Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more Feedback Charts.
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more Feedback Charts.